Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;10(1):119-134.
doi: 10.1007/s13300-018-0539-5. Epub 2018 Nov 27.

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Tomoya Mita  1 , Toru Hiyoshi  2 , Hidenori Yoshii  3 , Hiroko Chimori  4 , Kazuo Ikeda  5 , Miho Shimizu  6 , Yuichi Kojima  7 , Hareaki Yamamto  8 , Daijiro Yasuda  9 , Junko Sato  10 , Hirotaka Watada  11
Affiliations

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Tomoya Mita et al. Diabetes Ther. 2019 Feb.

Abstract

Introduction: There have been no studies directly comparing the effect of dipeptidyl peptidase-4 inhibitors with that of metformin on treatment-related quality of life (QOL) when used as first-line therapy in patients with type 2 diabetes mellitus (T2DM).

Methods: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Forty-four participants who failed to achieve target glycemic control with diet and exercise therapy were randomly allocated to receive linagliptin or metformin therapy. We compared treatment-related QOL among the two groups using the Oral Hypoglycemic Agent Questionnaire, version 2 (OHA-Q version 2) and the self-administered Diabetes Therapy-Related QOL (DTR-QOL) questionnaire.

Results: After randomization, 21 patients in the linagliptin group and 22 patients in the metformin treatment group were included in the full analysis set. Biochemical parameters, incidence of adverse effects, and rate of adherence to medication were comparable between the two groups. Over the 24-week treatment period, no significant differences in overall OHA-Q scores between the groups were observed, although the subscale 1 (treatment convenience) score was significantly higher in the linagliptin group than in the metformin group. The overall DTR-QOL score did not differ between the two groups; however, the DTR-QOL scores significantly improved after 24 weeks of linagliptin treatment, but not after metformin treatment.

Conclusion: We did not find significantly better treatment-related QOL with linagliptin among Japanese patients with T2DM. In terms of treatment convenience, our data showed that linagliptin was superior to metformin.

Funding: This study was financially supported by Nippon Boehringer Ingelheim Co., Ltd. and Eli Lilly and Company. The journal's article processing fees were covered by a research fund from Juntendo University.

Clinical trial registration: UMIN000022953.

Keywords: Linagliptin; Metformin; Questionnaire; Treatment-related quality of life; Type 2 diabetes mellitus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig. 2017;8(1):123–125. doi: 10.1111/jdi.12600. - DOI - PMC - PubMed
    1. Papazafiropoulou AK, Bakomitrou F, Trikallinou A, Ganotopoulou A, Verras C, Christofilidis G, et al. Diabetes-dependent quality of life (ADDQOL) and affecting factors in patients with diabetes mellitus type 2 in Greece. BMC Res Notes. 2015;8:786. doi: 10.1186/s13104-015-1782-8. - DOI - PMC - PubMed
    1. Yfantopoulos J, Hatzikou M, Rombopoulos G, Panitti E, Latsou D. The prevalence of hypoglycemia and its impact on the quality of life of type 2 diabetes mellitus patients in Greece (the Hypo study) Value Health. 2014;17(7):A356. doi: 10.1016/j.jval.2014.08.759. - DOI - PubMed
    1. Depablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, Derivas-Otero B, Garcia-Sanchez R, Viguera-Ester P. Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results in Spain of the PANORAMA study. Endocr Nutr. 2014;61(1):18–26. doi: 10.1016/j.endonu.2013.05.005. - DOI - PubMed
    1. Imayama I, Plotnikoff RC, Courneya KS, Johnson JA. Determinants of quality of life in adults with type 1 and type 2 diabetes. Health Qual Life Outcomes. 2011;9:115. doi: 10.1186/1477-7525-9-115. - DOI - PMC - PubMed

LinkOut - more resources